Neoantigens and Therapeutic Vaccines for Cancer (NeoVaCan)


Principal Investigator: Núria de la Iglesia


Our group conducts research using multi-omics and immune characterization of solid tumours and liquid biopsies at several layers, with the goal of taking cancer patient therapy towards personalization and achieving a better understanding of tumour genomic and immune heterogeneity.

With IrsiCaixa Cell Virology and Immunology (VIC) group and Barcelona Supercomputing Center teams, our group is working on co-developing a therapeutic neoantigen cancer vaccine for clinical application. As one of the two pillars of cancer vaccine development at IrsiCaixa, our group will coordinate the clinical side, translating next-generation sequencing-guided and experimental analyses of neoantigen prediction to therapeutic benefits for patients with cancer.

Keywords: cancer, genomics, neoantigens, bioinformatics, biomarkers, vaccine
Principal Investigator

Núria de la Iglesia

Dr. Núria de la Iglesia is a senior postdoctoral researcher in the Neoantigens and Therapeutic Vaccines for Cancer (NeoVaCan) group. She obtained her PhD training in the laboratory of Dr. Joan Guinovart at the University of Barcelona, studying...


Subscribe to our newsletter

Back to Top
Irsi Caixa

Promoted by:

'La Caixa' Foundation Generalitat de Catalunya - Departament de Salut


HR Excellence in Research

Member of:


In cooperation with: